Anatara Lifesciences Ltd · ASX:ANR
Anatara Lifesciences — Shareholder Meeting (November 2017)
18 slides from Anatara Lifesciences's shareholder meeting presentation, Nov 13, 2017
Slide 1: Annual General Meeting
Annual General Meeting For personal use only 13 November 2017
Slide 2: Disclaimer
Disclaimer For personal use only The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anatara Lifesciences Ltd, ACN
Slide 3: Investment Highlights
Investment Highlights For personal use only • Anatara is commercialising non-antibiotic oral products for gastrointestinal disease in animals and humans where there is a significant unmet need • Company well funded with $9.6m in bank • Strong growth since IPO, with share price up 305% since listing
Slide 4: Key Financial Details
Key Financial Details For personal use only ASX Code Market Share Price1 Capitalisation1 ANR $78.1 million $1.58 Current Cash2 Ordinary Shares Share Price $9.6 million 49,413,236 up 305% since IPO 1. As at 9 November 2017 2. Appendix 4C - 30 September 2017 4
Slide 5: ANR Share Price Chart
ANR Share Price Chart For personal use only Share price from IPO to 9 November 2017 5
Slide 6: Key Investor Message
Key Investor Message For personal use only The Anatara team is focussed on delivering commercial outcomes through application of the Company’s technology in both the pork industry, and in human health. More than ever, the world is looking for safe and effective solutions to gut health. 6
Slide 7: Key FY17 Achievements
Key FY17 Achievements For personal use only • Submission of dossier to the APVMA, seeking Detach® regulatory approval • In negotiation with #1 global animal health company, Zoetis Inc, for a worldwide commercial agreement for Detach® • Revenue up 12.6% to $3.2 million1 • Commercial readiness for Aus
Slide 8: Key FY17 Achievements Cont.
Key FY17 Achievements Cont. For personal use only • ~$840,000 R&D tax refund received for 2015-16 activities • Research facility established in Melbourne and R&D team expanded • $315,000 Science and Industry Endowment Fund’s (SIEF) STEM+ Business Fellowship Program Grant received to develop the huma
Slide 9: Key FY17 Achievements Cont.
Key FY17 Achievements Cont. For personal use only • Target Animal Safety Study completed – confirming Detach® is safe • “No Maximum Residue Limit” status granted by the European Medicines Authority (EMA) for bromelain, the active pharmaceutical ingredient in Detach® • Positive regulatory meetings wi
Slide 10: Need to combat antimicrobial resistance (AMR)
Need to combat antimicrobial resistance (AMR) “We have reached an historic turning point. We must not let this moment For personal use only pass. The cost of inaction would be unbearable.”’ Dr Tedros, Director-General, World Health Organisation (WHO) 2017 UNGA AMR driven by the overuse of antimicrob
Slide 11: Detach® - Commercial Readiness
Detach® - Commercial Readiness For personal use only • Commercially validated, supported by demand • APVMA review of this application is currently underway and has met all prospective review timelines • Anticipated Australian product launch in 2018 • Manufacturing tested at commercial scale • Market
Slide 12: Zoetis at a glance
Zoetis at a glance For personal use only • Zoetis (zō-EH-tis) are the #1 global animal health company • 60+ years of experience in animal health • 120+ countries in which Zoetis products are sold • ~$5 billion annual revenue – 65% revenue from farm animal products – 34% revenue from companion animal
Slide 13: What Next? Detach® - A Pipeline in a Product
What Next? Detach® - A Pipeline in a Product For personal use only Potential product extensions for the active components of Detach® Partnering and Development Opportunities for: – Human gastrointestinal conditions (diarrhoea; inflammatory bowel disease; irritable bowel syndrome) 13
Slide 14: Anatara technology – for humans
Anatara technology – for humans For personal use only Anti-secretory and anti-inflammatory action of Detach® actives may be used to control diarrhoea in gastrointestinal conditions, such as: • Inflammatory bowel disease • Irritable bowel syndrome and • Traveller’s diarrhoea Disorders of significant
Slide 15: Google 'Gut Health Books'
Google ‘Gut Health Books’ For personal use only 15
Slide 16: Major Market Opportunity for Anatara
Major Market Opportunity for Anatara Human GI disorders/disease For personal use only • Substantial patient population with unmet need despite availability of numerous therapies • GI disorders are highly symptomatic and a common reason why people seek medical treatment • GI disorders are associated
Slide 17: Detach® for Humans – Development Plans
Detach® for Humans – Development Plans For personal use only Goal • To develop proprietary bromelain-based medical foods and/or dietary supplements for the management of diarrhoea associated with gastrointestinal disorders Strategy • Leverage off the strong preclinical data obtained on Detach® • Und
Slide 18: Thank you
Thank you For personal use only Anatara’s naturally derived products will offer safe and effective non antibiotic solutions for gastrointestinal diseases. The Company is uniquely positioned to fulfil a currently unmet need in the global health market. Dr Mel Bridges, CEO & Chairman, Anatara Lifescie
Anatara Lifesciences — Shareholder Meeting (November 2017) on 6ix